1. Home
  2. HDB vs GILD Comparison

HDB vs GILD Comparison

Compare HDB & GILD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo HDFC Bank Limited

HDB

HDFC Bank Limited

HOLD

Current Price

$33.12

Market Cap

169.7B

Sector

Finance

ML Signal

HOLD

Logo Gilead Sciences Inc.

GILD

Gilead Sciences Inc.

HOLD

Current Price

$121.61

Market Cap

154.7B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
HDB
GILD
Founded
1994
1987
Country
India
United States
Employees
N/A
N/A
Industry
Commercial Banks
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
169.7B
154.7B
IPO Year
N/A
1992

Fundamental Metrics

Financial Performance
Metric
HDB
GILD
Price
$33.12
$121.61
Analyst Decision
Buy
Analyst Count
0
21
Target Price
N/A
$128.62
AVG Volume (30 Days)
4.9M
6.4M
Earning Date
01-18-2026
02-10-2026
Dividend Yield
1.16%
2.60%
EPS Growth
N/A
6514.05
EPS
0.53
6.42
Revenue
$30,210,861,338.00
$29,087,000,000.00
Revenue This Year
N/A
$3.63
Revenue Next Year
$9.77
$3.10
P/E Ratio
$19.35
$18.96
Revenue Growth
N/A
2.79
52 Week Low
$28.89
$89.02
52 Week High
$39.81
$128.70

Technical Indicators

Market Signals
Indicator
HDB
GILD
Relative Strength Index (RSI) 30.57 48.53
Support Level $36.02 $119.33
Resistance Level $33.59 $124.48
Average True Range (ATR) 0.57 2.81
MACD -0.26 -0.13
Stochastic Oscillator 6.90 46.58

Price Performance

Historical Comparison
HDB
GILD

About HDB HDFC Bank Limited

HDFC Bank Ltd is an Indian bank. It operates in the following segments: Treasury, Retail banking, Wholesale banking, and Other banking business. The maximum revenue for the company is generated from its Retail banking segment, which serves retail customers through its branch network and other channels. This segment raises customer deposits and provides loans and other services to customers using different product groups. Its other operations include providing wholesale banking services to corporates, government entities, and other enterprises, generating income from its treasury operations, and performing para-banking activities such as offering credit cards, debit cards, etc. Geographically, the company generates a majority of its revenue from its operations in India.

About GILD Gilead Sciences Inc.

Gilead Sciences develops and markets therapies to treat and prevent life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of newer combination regimens that remain standards of care. Gilead is also growing its presence in the oncology market via acquisitions, led by CAR-T cell therapy Yescarta/Tecartus (from Kite) and breast and bladder cancer therapy Trodelvy (from Immunomedics).

Share on Social Networks: